Breast ductal carcinoma in situ: a literature review of adjuvant hormonal therapy
Keyword(s):
This review paper analyzed publications of adjuvant tamoxifen and aromatase inhibitor use following surgery for breast ductal carcinoma in situ (DCIS). Key endpoint analyses were risk of invasive and noninvasive malignancies and new contralateral breast cancers. Meta-analysis of three studies showed a relative risk of 0.69 (95% confidence interval, 0.60-0.79, P<0.05) for breast malignancies with tamoxifen treatment in a mixed radiotherapy treatment/naïve cohort. Subgroup analysis of DCIS populations in multiple studies showed a trend to benefit with aromatase inhibitor treatment.
2012 ◽
Vol 23
(4)
◽
pp. 346-348
1997 ◽
Vol 13
(3)
◽
pp. 420-429
◽
2011 ◽
Vol 29
(15_suppl)
◽
pp. 1042-1042
Keyword(s):
2016 ◽
Vol 34
(15_suppl)
◽
pp. 1020-1020
2010 ◽
pp. 213-218
2012 ◽
Vol 23
(2)
◽
pp. 165-166
◽